# Phase 1/2 Neoplasm Metastasis trials recruiting: 93 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 93 trials in phase 1/2 for Neoplasm Metastasis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Neoplasm Metastasis trials: 93 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/neoplasm-metastasis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 93
- Recruiting or not yet: 93
- Read on: November 19, 2026

## Trials

The 25 newest of 93, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07944144 | A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer... | Ipsen | Phase 1/2 | Not yet recruiting | Neoplasms, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes | 205 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944144) |
| November 12, 2026 | NCT07933055 | Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan... | Txinno Bioscience Inc. | Phase 1/2 | Recruiting | NSCLC (Non-small Cell Lung Cancer) | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933055) |
| November 2, 2026 | NCT07909031 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)... | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909031) |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 7, 2026 | NCT07863024 | Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Advanced Solid Tumors | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863024) |
| August 13, 2026 | NCT07762703 | Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS\<10), gBRCA Negative, Triple... | BreakBio Corp | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762703) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| July 31, 2026 | NCT07738341 | GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) | Eddingpharm (Zhuhai) Co., Ltd. | Phase 1/2 | Recruiting | Breast Cancer (Locally Advanced or Metastatic) | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738341) |
| July 23, 2026 | NCT07723482 | ML-016 in Advanced Cancer With Lung and/or Liver Involvement | BrYet US, Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor With Lung and/or Liver Involvement | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723482) |
| July 14, 2026 | NCT07701486 | A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer | Theriva Biologics SL | Phase 1/2 | Recruiting | Pancreas Cancer, Metastatic, Pancreas Cancer, Stage IV, Ductal Adenocarcinoma of the Pancreas | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07701486) |
| July 9, 2026 | NCT07693751 | A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer | SOTIO Biotech a.s. | Phase 1/2 | Recruiting | Colorectal Cancer (Locally Advanced or Metastatic) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07693751) |
| June 24, 2026 | NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer | University Health Network, Toronto | Phase 1/2 | Not yet recruiting | Pancreas Ductal Adenocarcinoma, Pancreas Cancer, Metastatic, Pancreatic Adenocarcinoma Metastatic, Adenosquamous... | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07665684) |
| June 23, 2026 | NCT07662720 | A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer | Glycyx Therapeutics | Phase 1/2 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662720) |
| June 11, 2026 | NCT07641023 | Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC | Beijing Biotech | Phase 1/2 | Recruiting | Non-Small Cell Lung Cancer, Advanced/Metastatic | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641023) |
| June 5, 2026 | NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | Blueprint Medicines Corporation | Phase 1/2 | Recruiting | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629960) |
| June 4, 2026 | NCT07627711 | Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | Beijing Biotech | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, Metastatic Disease | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627711) |
| May 29, 2026 | NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With... | Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1/2 | Recruiting | Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer, Ovarian... | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612891) |
| May 28, 2026 | NCT07610798 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced... | Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1/2 | Recruiting | Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced... | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610798) |
| May 22, 2026 | NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | InduPro, Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma... | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602842) |
| May 19, 2026 | NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | Northwestern University | Phase 1/2 | Recruiting | Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Malignant... | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594626) |
| April 13, 2026 | NCT07523529 | Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Unresectable, Metastatic | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523529) |
| April 6, 2026 | NCT07510802 | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | Beijing Biotech | Phase 1/2 | Recruiting | Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510802) |
| April 3, 2026 | NCT07509008 | Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric... | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | Gastric Cancer, Metastatic | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509008) |
| March 20, 2026 | NCT07486089 | Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) | Beijing Biotech | Phase 1/2 | Recruiting | Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486089) |
| March 18, 2026 | NCT07480928 | Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | Beijing Biotech | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480928) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 6 |
| [Ipsen](https://specstream.ai/data/clinical-trials/company/ipsen) | 3 |
| GI Innovation, Inc. | 3 |
| Shenzhen Ionova Life Sciences Co., Ltd. | 2 |
| Essen Biotech | 2 |
| Nuvalent Inc. | 2 |
| Avenzo Therapeutics, Inc. | 2 |
| Crescent Biopharma, Inc. | 2 |
| M.D. Anderson Cancer Center | 2 |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 2 |
| Artios Pharma Ltd | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| Cerenome | 1 |
| Onchilles Pharma Inc | 1 |
| CHU de Quebec-Universite Laval | 1 |
| Engeneic Pty Limited | 1 |
| National Cancer Institute (NCI) | 1 |
| Parabilis Medicines, Inc. | 1 |
| Kidney Cancer Research Bureau | 1 |
| QuantumLeap Healthcare Collaborative | 1 |
| University Health Network, Toronto | 1 |
| PMV Pharmaceuticals, Inc | 1 |
| Nykode Therapeutics ASA | 1 |
| BreakBio Corp | 1 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 58 |
| Spain | 22 |
| Australia | 20 |
| South Korea | 18 |
| France | 18 |
| China | 17 |
| United Kingdom | 10 |
| Germany | 9 |
| Italy | 9 |
| Canada | 7 |
| Belgium | 5 |
| Netherlands | 5 |
| Singapore | 5 |
| Taiwan | 5 |
| Japan | 4 |
| Poland | 4 |
| Puerto Rico | 3 |
| Israel | 3 |
| Norway | 2 |
| New Zealand | 2 |
| Portugal | 2 |
| Ireland | 2 |
| Ukraine | 2 |
| Russia | 1 |
| Hungary | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hostels in the United States](https://specstream.ai/data/businesses/hostels/united-states)
- [Bearing suppliers in the United States](https://specstream.ai/data/businesses/bearing-suppliers/united-states)
- [Real estate investment firms in the United States](https://specstream.ai/data/businesses/real-estate-investment-firms/united-states)
- [Graphic design firms in the United States](https://specstream.ai/data/businesses/graphic-design-firms/united-states)
- [B2B oil and gas companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-companies/united-states)
- [Printing companies in the United States](https://specstream.ai/data/businesses/printing-companies/united-states)
